View on market: Volatility persists, eagerly searching for growth:
Global markets remained cautious as investors tracked developments in the Middle East and their potential impact on energy supplies and global trade. Asian markets traded mostly higher, with Japan leading the gains and Australia also closing in positive territory. However, overall sentiment remained mixed as geopolitical concerns continued to keep investors alert. In the United States, Wall Street paused after a strong rally as investors awaited greater clarity on the situation between the US and Iran. Major indices opened lower, reflecting cautious sentiment and profit booking near record highs. Technology stocks also witnessed some cooling after recent gains. Despite the weak start, investors continued to monitor global risks and economic developments, keeping overall market sentiment resilient. Indian markets snapped their recent losing streak and ended higher. Technology stocks led the recovery and supported benchmark indices, while gains were partially offset by weakness in select banking, financial and energy stocks. The positive close reflected improved investor confidence, although market participants remained watchful of global developments and their potential impact on domestic markets.
Economic Calendar:
- USD: S&P Global and ISM Services PMI and S&P Global Composite PMI Data on 03rd June 2026.
- IND: HSBC Composite and Services PMI Data on 03rd June 2026.
- USD: Continuing and Initial Jobless Claims Data on 04th June 2026.
- IND: Monetary Policy on 05th June 2026.
BROKERAGE RADAR:
JEFFERIES ON MANKIND PHARMA:
Target ₹3000 Recommendation Buy, Turning the corner amid lingering skepticism, Improvement in volume growth signals volume revival in acute therapy, Consistent chronic segment distribution, Bharat Serum exports to witness high teens growth in FY27, Clinical pipeline-future optionality.
MORGAN STANLEY ON JSW STEEL:
Target ₹1330 Recommendation Overweight, Targeting 50MT of domestic crude steel capacity by 2030, Ilwara supply, Mozambique commissioning and domestic mines expansion should cover 50% of coking coal requirements, To maintain EBIDTA/ton in range of Rs 11-12k/ton, Looks to keep net debt/EBIDTA ratio below 3x.
MORGAN STANLEY ON HDB FINANCIAL:
Target ₹720 Recommendation Equal-Weight, Collections and loan demand has remained stable, Loan growth aspiration remains nominal GDP growth+6-7% over medium term, Aims to sustain NIM above 8% in near to medium term, Sligh potential increase in costs of funds in Q2FY27, Overall credit costs in range of 23-bps in medium term.
MORGAN STANLEY ON HINDALCO:
Target ₹1325 Recommendation Overweight, Overall power costs should moderate by ~30%, implying ~12-13% reduction in overall costs, China’s supply cap, Middle East supply disruption and falling LME inventories should keep LME aluminium prices supported in the near term, EBITDAs should start improving 2Q-F27 onwards as Oswego restarts, and should turn cash positive by 4Q-F27 end, Re-iterated insurance recoveries of ~70-75% of overall losses from fire incidents, implying US$1.2-1.3 billion of recoveries.
International Markets:
U.S & Europe:
| Particulars | 02nd June | Chg. | Chg.(%) |
| Nasdaq | 27,093.90 | 7.09 | 0.03 |
| Dow | 51,307.79 | 228.91 | 0.45 |
| FTSE | 10,373.51 | 34.56 | 0.33 |
| CAC | 8,209.09 | 62.50 | 0.77 |
| DAX | 25,124.17 | 121.13 | 0.48 |
| Dow Fut.* | 51,381.00 | -19.00 | -0.04 |
*As per 03rd June.
Asian markets:
| Particulars | 03rd June | Chg. | Chg.(%) |
| GIFT Nifty | 23,477.00 | -126.10 | -0.53 |
| Nikkei | 68,451.00 | 1,716.76 | 2.57 |
| Straits Times | 5,142.42 | 45.00 | 0.88 |
| Hang Seng | 25,662.00 | -375.32 | -1.44 |
| Shanghai | 4,082.34 | 7.24 | 0.18 |
Stocks strong on Chart:
| Index | F&O | Cash |
| INFOSYS | EXIDE | NEWZEN SOFT |
| TCS | LTM | BALAJI AMINES |
| TECH MAH | TATAELXSI | ALKYL MAINES |
| TMPV | KPIT | HLE GLASSCOAT |
| INDIGO | PERSISTENT | ACME SOLAR |
| HCL TECH | COFORGE | APOLLO MICRO |
Commodities & Currency:
| Particulars | Current Price | Chg. (%) |
| USD/INR | 95.342 | 0.09 |
| Brent | 96.69 | 0.72 |
| Gold | 154,750 | -0.51 |
| Silver | 266,522 | 0.13 |
FIIs & DIIs:
| Particulars | 02nd June | 01st June |
| FIIs | -8,362.92 | -3,911.68 |
| DIIs | 9,589.32 | 5,109.13 |
View on market: Volatility persists, eagerly searching for growth
News Updates:
| Infosys: | It expands its partnership with DNB Bank ASA to enhance financial crime management operations. |
| Canara Bank: | It approves a capital raising plan of up to Rs. 8,500 crore through bonds during FY27. |
| Mankind Pharma: | Its subsidiary acquires the remaining 10% stake in Upakarma, securing complete ownership. |
| United Foodbrands: | NCLT approves the merger of Blue Planet Foods with Red Apple Kitchen. |
| Wipro: | It completes the acquisition of an additional 20% stake in Aggne Global Inc. |
| John Cockerill India: | It secures an order worth around Rs. 1,300 crore from JSW Vijayanagar Metallics for commissioning two annealing and coating lines. |
| Patanjali Foods: | It receives a tax demand of Rs. 73 crore for FY23 over alleged ineligible input tax credit claims. |
| Concord Biotech: | It receives US FDA approval for its Mycophenolate Mofetil ANDA, used to prevent organ rejection, with an estimated US market opportunity of USD 30 million. |
Source: Moneycontrol, Bloomberg Quint, Investing
Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014
Elite Wealth Limited (Elite Wealth Limited is wholly owned subsidiary of InCred Capital Financial Services Limited) does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India. (SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Vindhyachal Prasad, Elite Wealth Limited, vindhyachal@elitestock.com
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
- All of the views expressed in the report accurately reflect his or her personal views about any and all of
the subject securities or issuers; and
- No part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale. Legal
Entities Disclosures
Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
- Reports
- EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
- EWL or its associates or relatives, have no actual/beneficial ownership of one %. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
- EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
- Compensation
- EWL or its associates have not received any compensation from the subject company in the past twelve months;
- EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
- EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
- EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
- EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research
- In respect of Public Appearances
- EWL or its associates have not received any compensation from the subject company in the past twelve months;
- The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL




